Background
==========

BACH1 (BRCA1-associated C-terminal helicase 1, also known as BRCA1-interacting protein 1, BRIP1; GenBank: [NM_032043](NM_032043)) belongs to a DEAH helicase family and interacts *in vivo*with BRCA1, the protein product of one of the two major genes for hereditary breast cancer susceptibility \[[@B1],[@B2]\]. Interaction is mediated through BRCT domains of BRCA1, motifs that have been shown to be important for the ability of BRCA1 to mediate double-strand break repair and homologous recombination as well as transcription activation \[[@B3],[@B4]\]. The *BACH1*gene is located at chromosome region 17q23. Besides genes known to be involved in the development and progression of breast cancer, such as *BRCA1*at 17q21 and *ERBB2*at 17q12, the presence of other breast cancer associated genes, both tumor suppressors and oncogenes, have been proposed in the long arm of chromosome 17 on the basis of loss of heterozygosity, allelic imbalance, and comparative genomic hybridization studies \[[@B5]-[@B9]\]. The possibility of a tumor suppressor gene located distal to *BRCA1*and involved in both sporadic and hereditary ovarian cancer has also been discussed \[[@B10]-[@B12]\].

Previously, Cantor and co-workers have reported on *BACH1*germ line missense mutations in early-onset breast cancer patients, with one of the patients having a strong family history of both breast and ovarian cancer \[[@B2]\]. In subsequent functional analysis both of the observed mutations, Pro47Ala that is located in a highly conserved nucleotide binding domain and Met299Ile that resides in a helicase homology region, were shown to perturb BACH1 protein function by altering both ATPase and helicase activity \[[@B13]\]. In addition to these rare mutations in individual families, a common Ser-allele of the Ser919Pro polymorphism has recently been associated with an increased breast cancer risk; in a kin-cohort study a 4.5-fold and up to 6.9-fold increased cumulative breast cancer risk was seen for the first degree relatives of Pro/Ser and Ser/Ser carriers vs. Pro/Pro carriers, respectively, by the age of 50 years \[[@B14]\].

Interestingly, biallelic inactivation of *BACH1*was recently observed in patients with Fanconi Anemia (FA), a recessive chromosomal instability disorder characterized by developmental abnormalities, growth retardation, bone marrow failure, and early predisposition to cancer \[[@B15],[@B16]\]. *BACH1*mutations were observed in patients with FA complementation group J, whereas similar inactivation of *BRCA2*has been previously observed in patients with FA complementation group D1 \[[@B17]\]. As individuals with a heterozygous *BRCA2*mutation are known to have a markedly elevated risk for developing breast cancer, it\'s tempting to speculate that a similar effect could also be seen with *BACH1*. In epidemiological studies an excess of breast cancer cases, although statistically non-significant, have been observed among FA heterozygotes \[[@B18]\]. However, this observation needs to be taken cautiously due to the small sample size and lack of analyses of individual complementation groups.

In this study, we aimed to evaluate whether there are *BACH1*genetic variants that contribute to breast cancer risk by screening the *BACH1*gene for germ line alterations among 43 Finnish *BRCA1/2*negative breast cancer families. We also evaluated the Ser919Pro variant in a large, independent series of 888 unselected breast cancer patients and in 736 healthy controls.

Methods
=======

Breast cancer patients and healthy controls
-------------------------------------------

Breast cancer patients belonging to 43 breast cancer families with at least three breast or ovarian cancer cases in 1^st^or 2^nd^degree relatives and with no detectable *BRCA1/2*mutations were included in the initial mutation analysis. Recruitment of the families through the Department of Oncology, Helsinki University Central Hospital, Finland as well as verification of the cancer diagnoses and exclusion of the *BRCA1*and *BRCA2*mutations have been previously described \[[@B19]-[@B21]\].

The *BACH1*variant Ser919Pro was analyzed in a large series of unselected breast cancer patients and healthy controls. The 888 unselected breast cancer patients were collected at the Helsinki University Central Hospital, Finland, during April 1997-March 1998 \[[@B22]\] and January-June 2000 \[[@B23]\], and cover 79% of all consecutive, newly diagnosed breast cancer cases during the collection period. DNA samples from altogether 736 healthy females collected at the same geographical region of Southern Finland were studied as healthy population controls. As the variant was associated with an increased breast cancer risk by the age of 50 years \[[@B14]\] the study cohort as well as the population controls were subgrouped according to the menopausal status (age 50 years was chosen as a surrogate for menopause, and patients with cancer diagnosis at \< 50 years were considered premenopausal and ≥50 years as postmenopausal). Breast tumor characteristics (tumor histology, size, and grade; nodal and distal metastasis; estrogen and progesterone receptor status) were available from all patients. Additionally, a Val193Ile variant that was found in only one family in the initial mutation analysis was further genotyped in randomly selected series of 346 familial breast cancer patients and in 183 healthy population controls. All mutation analyses have been performed on DNA samples extracted from peripheral blood.

The study was performed with informed consent from the patients and under appropriate research permissions from the Ethics Committees of the Departments of Obstetrics and Gynecology, and Oncology, Helsinki University Central Hospital, Finland, as well as Ministry of Social Affairs and Health in Finland.

Mutation analysis
-----------------

The coding region and exon-intron boundaries of *BACH1*were screened using conformation sensitive gel electrophoresis (CSGE) with modifications previously described \[[@B24]\]. Samples with aberrant CSGE profiles were reamplified, and the nucleotide changes determined by direct sequencing. Primers and PCR conditions used in the mutation analysis are presented in table [1](#T1){ref-type="table"}. The frequency of the Ser919Pro alteration was determined by Amplifluor™ fluorescent genotyping (K-Biosciences, Cambridge, UK). The genotyping for nt c.2755 (codon 919) was successful in 866/888 (97.5%) breast cancer patient samples and in 731/736 (99.3%) healthy control samples. The Val193Ile (c.577G\>A) variant was genotyped in 346 (successful in 336, 97.1%) familial breast cancer samples and in 183 (successful in 167, 91.3%) control samples, respectively, by Amplifluor™ fluorescent genotyping as well.

Statistical analysis
--------------------

Possible associations between the *BACH1*Ser919Pro and breast cancer risk, as well as the variant and clinico-pathologic features of the tumors, were tested by univariate analysis. Independent variables were compared with the chi-square test. The mean age at breast cancer diagnoses between the carriers and non-carriers was compared by one-way ANOVA. All p-values were 2-sided, and p-value \< 0.01 was considered statistically significant as suggested by Houlston and Peto \[[@B25]\]. All statistical analyses were carried out in the SPSS software (version 12.0 for Windows, SPSS, Chicago, IL, USA).

Results and discussion
----------------------

Altogether six germ line *BACH1*variants were observed in the initial mutation analysis (Table [2](#T2){ref-type="table"}). Four of the changes were in the coding region, two of these were missense and two silent substitutions. The missense changes were analyzed further for their possible association with breast cancer risk. The silent alterations have been suggested as neutral polymorphisms by the previous studies \[[@B2],[@B26],[@B27]\], and were not studied here further. The one missense substitution, Val193Ile, was seen in only one family. In addition to the proband diagnosed with breast cancer at the age of 54 years, the variant was also seen in her healthy father and healthy brother, father\'s sister diagnosed with skin cancer at age 85 years, and the aunts\' three children diagnosed with breast cancer at 63 years, ovarian cancer at 59 years, and skin cancer at 64 years, respectively. The grandmother of the proband, whose carrier status is unknown, has been diagnosed with breast cancer at age 74 years. The variant was not observed among 336 familial breast cancer patients or in 167 healthy population controls. It has previously been observed in 3/200 (1.5%) healthy controls and classified as a rare polymorphism \[[@B2]\]. The residue resides in close proximity to the ATP/GTP binding site, and the possible functional significance of this rare variant to BACH1 protein function remains to be determined.

The other observed missense substitution, a common polymorphism Ser919Pro, was associated with an elevated breast cancer risk during the course of this study \[[@B14]\]. In that study the relative cumulative risk by the age 50 years was 4.5 for the female first degree relatives of Pro/Ser heterozygotes (95% CI 0.8--12.2; p = 0.096) and up to 6.9 (95% CI 1.6--29.3; p = 0.018) for the first degree relatives of Ser/Ser homozygotes, when compared to Pro/Pro homozygotes. However, no significant association was seen when the analysis was extended to age 70 years (OR 1.3, 95%CI 0.8--2.8, p = 0.220) \[[@B14]\]. Here we found no association of the variant with breast cancer risk. The odds ratios for the whole study cohort as well as for the pre- and postmenopausal patient groups were close to one both for the Pro/Ser heterozygotes and for the Ser/Ser homozygotes when compared to Pro/Pro homozygotes (Table [3](#T3){ref-type="table"}). The alteration did not associate with breast cancer family history (data not shown). No association of the variant with any of the breast tumor characteristics (Table [4](#T4){ref-type="table"}) or survival (data not shown) was seen either, and also the age at breast cancer diagnosis was similar in all genotype carrier groups (56.9 years for the Pro/Pro homozygotes, 56.8 years for the heterozygotes, and 56.1 years for the Ser/Ser homozygotes, respectively; p = 0.705). Our data suggest that the *BACH1*Ser919Pro alteration is not a breast cancer predisposition allele in our study population although a very low risk effect cannot be excluded. A joint effect on breast cancer risk by the Ser919Pro variant and other epidemiological risk factors may also be possible.

Our data, together with previous studies, suggest that germ line mutations in *BACH1*do not substantially contribute to the remaining proportion of the familial aggregation of breast cancer outside the high-penetrance genes *BRCA1*and *BRCA2*\[[@B2],[@B26]-[@B28]\]. In the future, it will be interesting to see whether the heterozygous *BACH1*mutation carriers in FA families have an excess risk of developing breast or other type of cancer. So far, heterozygous mutations of the FA genes, with the exception of *BRCA2*, have been found to be extremely rare, or nonexistent, in breast cancer families \[[@B29]\], and the studied polymorphisms have not been found to confer an increased risk for breast cancer \[\[[@B30]\], this study\].

Conclusion
==========

Taken together, our results are in concordance with previous studies where germ line *BACH1*mutations have been observed in only a very few familial breast cancer patients \[[@B2],[@B26]-[@B28]\]. This suggests that even though some functionally deleterious germ line *BACH1*mutations have been observed in breast cancer patients, such mutations are rare and may account for only a very small proportion, if any, of non-*BRCA1/2*familial breast cancer. Our results further indicate that *BACH1*Ser919 is not a breast cancer predisposition allele in the Finnish population.
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Figures and Tables
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###### 

Primers and PCR conditions used in *BACH1*mutation analysis.

  **Exon**   **Strand**   **Primer name**   **Nucleotide sequence (5\'→3\')**   **Amplicon lenght (bp)**   **Annealing temperature (°C)**
  ---------- ------------ ----------------- ----------------------------------- -------------------------- --------------------------------
  2          Forward      Ex2F              CTGTTTCCAGATTTCTCCC                                            
             Reverse      Ex2R              GTGAACCCAGAAAATATTCTCC              331                        58
  3          Forward      Ex3F              CCCTGGAGTGCAATCTCACT                                           
             Reverse      Ex3RN             TAGCGACAGCATGGCTGAA                 319                        48
  4          Forward      Ex4F              CCTGGGTGAACTGGGCTGTAG                                          
             Reverse      Ex4RN             TAACAGTAATAATTAAGACTC               316                        48
  5          Forward      Ex5FN             TTGCCTACCTGTAAGTTATTTATG                                       
             Reverse      Ex5RN             ACCATGTTCAGCTGTAACTAACTG            233                        60
  6          Forward      Ex6F              GAGCTGTTTTGGCCTTTGAGA                                          
             Reverse      Ex6RN             CTGAGTGGGTTGCTACTGTCCT              317                        55
  7          Forward      Ex7F              GTTCTGATTCCATGTGAGGTT                                          
             Reverse      Ex7R              GTACATATAAAACACATACTGAGT            448                        55
  8          Forward      Ex8F              GATGTTCCTCAAATTCTGAGATAA                                       
             Reverse      Ex8R              CATCTAAAAGCTTTTACATTCAAC            386                        55
  9          Forward      Ex9F              GCCTATAGTGTGAATTTTAAAATG                                       
             Reverse      Ex9R              CCTAGTTAACCAAAGTTTACTAAC            395                        55
  10         Forward      Ex10F             GATCAACGCATGACAATAATGATG                                       
             Reverse      Ex10R             GGGTTACTCACTAGATTTAATCTG            320                        55
  11         Forward      Ex11F             GCATGTTTTGTTGGGTTTCATTGT                                       
             Reverse      Ex11R             GGTATGTATTAAACACATGCTAGC            326                        55
  12         Forward      Ex12F             GTACCAGCTCTTTCAAATGAG                                          
             Reverse      Ex12R             CTATCTTTAAAAGAGTCAACCAC             360                        55
  13         Forward      Ex13FN            GTGCTGGGATTACAGGTGTGAGCCA                                      
             Reverse      Ex13RN            ACTTGCTGGCACTTCAGGTATCTTC           317                        60
  14         Forward      Ex14F             CTTGTTGCTTGATCTTTTATGTAC                                       
             Reverse      Ex14R             CTAGGAAGCTTACTGTGGTAA               356                        55
  15         Forward      Ex15FN            ACAGCTCTATGAGATATATTG                                          
             Reverse      Ex15RN            TCATAGGAGAACAAGTACAAT               504                        55
  16         Forward      Ex16FN            TTACTTAAAGACATTGAACTT                                          
             Reverse      Ex16RNN           CACTATAAAAGCAAAGCGC                 392                        54
  17         Forward      Ex17FN            CTGTTAGAAGTTAATATGATG                                          
             Reverse      Ex17RN            GAATACATACCAGTTCCTATG               325                        55
  18         Forward      Ex18F             CCAATTTTCTGTCTGTCCCAC                                          
             Reverse      Ex18R             GATAGTAGAGCTCATGTTATGTG             254                        55
  19         Forward      Ex19F             CTTCACTAGAAAAAGCAAGTG                                          
             Reverse      Ex19R             CCACCATATTTAAGGAATTAATC             523                        48
  20A        Forward      Ex20AFN           ACCTAGCAATTATGTTAGCT                                           
             Reverse      Ex20ARN           TCTGTATCTTCAGGATCGTA                584                        48
  20B        Forward      Ex20BFN           ATTGATGCCACCCTTACTA                                            
             Reverse      Ex20BRNN          TAACATAAGCATGATGACATA               565                        54

###### 

Observed germ line variants in *BACH1*.

  **Exon/Intron**   **Nucleotide change**   **Amino acid change**   **Frequency for heterozygotes (%)**
  ----------------- ----------------------- ----------------------- -------------------------------------
  int5              508-31 C→G              \-                      11/43 (25.6)
  ex6               577 G→A                 Val193Ile               1/43 (2.3)
  int14             2097+7 G→A              \-                      1/43 (2.3)
  ex19              2637 G→A                Glu879Glu               31/43 (72.1)\*
  ex19              2755 C→T                Ser919Pro               32/43 (74.4)\*
  ex20              3411 C→T                Tyr1137Tyr              27/43 (62.8)\*

\* also homozygotes for the rare allele

###### 

Genotypes of the *BACH1*Ser919Pro variant among 866 unselected breast cancer patients and 731 healthy population controls.

                                                                **[Cases]{.ul}**   **[Controls]{.ul}**                                       
  ------------------------------------------------------------- ------------------ --------------------- ----- ------ ------- -------------- -------
  **Unselected breast cancer patients, all**                    866                                      731                                 
                                                                                                                                             
  Pro/Pro                                                       184                21.2                  148   20.2   1                      
  Pro/Ser                                                       428                49.4                  382   52.3   0.901   0.697--1.165   0.427
  Ser/Ser                                                       254                29.3                  201   27.5   1.016   0.765--1.351   0.911
  Pro/Ser + Ser/Ser                                             682                78.8                  583   79.8   0.941   0.738--1.120   0.623
                                                                                                                                             
  **Unselected breast cancer patients, diagnosis \<50 years**   276                                      476                                 
                                                                                                                                             
  Pro/Pro                                                       56                 20.3                  96    20.2   1                      
  Pro/Ser                                                       140                50.7                  249   52.3   0.964   0.653--1.423   0.853
  Ser/Ser                                                       80                 29                    131   27.5   1.047   0.680--1.611   0.835
  Pro/Ser + Ser/Ser                                             220                79.7                  380   79.8   0.993   0.686--1.436   0.968
                                                                                                                                             
  **Unselected breast cancer patients, diagnosis ≥50 years**    590                                      255                                 
                                                                                                                                             
  Pro/Pro                                                       128                21.7                  52    20.4   1                      
  Pro/Ser                                                       288                48.8                  133   52.2   0.878   0.600--1.289   0.511
  Ser/Ser                                                       174                29.5                  70    27.5   1.010   0.660--1.545   0.964
  Pro/Ser + Ser/Ser                                             462                78.3                  203   79.6   0.925   0.644--1.328   0.671

\* as compared to Pro/Pro homozygotes

###### 

Tumor characteristics of the 909 breast tumors from 866 breast cancer patientsanalyzed for the *BACH1*Ser919Pro variant.

                                                 ***BACH1*Ser919Pro**                             
  --------------------------------- ------------ ---------------------- ------------ ------------ -------
  **Histology**                     909                                                           
  Carcinoma ductale                 713 (78.4)   145 (76.3)             358 (78.7)   210 (79.5)   0.480
  Carcinoma lobulare                130 (14.3)   25 (13.2)              70 (15.4)    35 (13.3)    
  Carcinoma medullare               13 (1.4)     5 (2.6)                5 (1.1)      3 (1.1)      
  Other                             53 (5.8)     15 (7.9)               22 (4.8)     16 (6.1)     
                                                                                                  
  **Tumor grade**                   817                                                           
  1                                 223 (27.3)   51 (29.8)              116 (28.2)   56 (23.9)    0.702
  2                                 353 (43.2)   73 (42.7)              174 (42.2)   106 (45.3)   
  3                                 241 (29.5)   47 (27.5)              122 (29.6)   72 (30.8)    
                                                                                                  
  **Tumor size, pT**                887                                                           
  1                                 545 (61.4)   121 (65.8)             269 (60.7)   155 (59.6)   0.423
  2                                 282 (31.8)   47 (25.5)              148 (33.4)   87 (33.5)    
  3                                 31 (3.5)     7 (3.8)                15 (3.4)     9 (3.5)      
  4                                 29 (3.3)     9 (4.9)                11 (2.5)     9 (3.5)      
                                                                                                  
  **Lymph node status, pN**         909                                                           
  Negative                          477 (52.5)   104 (54.7)             223 (49.0)   150 (56.8)   0.101
  Positive                          432 (47.5)   86 (45.3)              232 (51.0)   114 (43.2)   
                                                                                                  
  **Distant Metastasis, pM**        870                                                           
  Negative                          829 (95.3)   168 (93.9)             416 (96.1)   245 (95.0)   0.478
  Positive                          41 (4.7)     11 (6.1)               17 (3.9)     13 (5.0)     
                                                                                                  
  **Estrogen receptor status**      862                                                           
  Positive                          680 (78.9)   139 (76.8)             339 (78.5)   202 (81.1)   0.530
  Negative                          182 (21.1)   42 (23.2)              93 (21.5)    47 (18.9)    
                                                                                                  
  **Pogesterone receptor status**   863                                                           
  Positive                          591 (68.5)   129 (70.9)             289 (66.9)   173 (69.5)   0.577
  Negative                          272 (31.5)   53 (29.1)              143 (33.1)   76 (30.5)    
